We are live on
!
Find out more
CA
Corriente Advisors Portfolio holdings
AUM
$9.53M
1-Year Est. Return
805.26%
This Fund
S&P 500
This Quarter
Est. Return
-7.72%
1 Year Est. Return
+805.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$272M
AUM Growth
-$149M
(-35%)
Cap. Flow
-$117M
Cap. Flow
% of AUM
-42.92%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
23
New
4
Increased
5
Reduced
1
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teledyne Technologies
TDY
|
+$21.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$13.5M |
| 3 |
Lantern Pharma
LTRN
|
+$12.5M |
| 4 |
Cardiff Oncology
CRDF
|
+$9.54M |
| 5 |
Cue Biopharma
CUE
|
+$8.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$64.9M |
| 2 |
Cameco
CCJ
|
+$29.2M |
| 3 |
GoPro
GPRO
|
+$27.7M |
| 4 |
MNDT
Mandiant, Inc. Common Stock
MNDT
|
+$15.9M |
| 5 |
APTO
Aptose Biosciences, Inc.
APTO
|
+$12.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.3% |
| 2 | Technology | 45.28% |
| 3 | Communication Services | 5.42% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAXR
1
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $100M | 36.9% |
2,650,000
+150,000
| +6% | +$6.68M |
|
2
Replimune Group
REPL
$859M
| $32.8M | 12.08% |
1,075,000
-160,000
| -13% | -$5.99M |
|
|
3
Cue Biopharma
CUE
$131M
| $31.1M | 11.45% |
84,968
+21,127
| +33% | +$8.69M |
|
|
4
Cardiff Oncology
CRDF
$60.2M
| $25.8M | 9.5% |
2,785,410
+785,410
| +39% | +$9.54M |
|
|
5
Teledyne Technologies
TDY
$29.4B
| $22.8M | 8.38% |
+55,000
| New | +$21.2M |
|
|
TFFP
6
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
| $21.2M | 7.82% |
62,627
+8,627
| +16% | +$3.51M |
|
|
7
Meta Platforms (Facebook)
META
$1.64T
| $14.7M | 5.42% |
+50,000
| New | +$13.5M |
|
|
8
Lantern Pharma
LTRN
$36.6M
| $12.9M | 4.77% |
+713,806
| New | +$12.5M |
|
9
DiaMedica Therapeutics
DMAC
$393M
| $7.96M | 2.93% |
870,228
+63,328
| +8% | +$592K |
|
10
EyePoint Inc
EYPT
$1.12B
| $2.03M | 0.75% |
+200,000
| New | +$2.25M |
|
|
11
Cameco
CCJ
$37.3B
| – | – |
-2,177,086
| Closed | -$29.2M |
|
|
CMPS
12
Compass Pathways
CMPS
$1.67B
| – | – |
-190,000
| Closed | -$9.05M |
|
13
Curis
CRIS
$9.02M
| – | – |
-2,750
| Closed | -$9.01M |
|
|
14
GoPro
GPRO
$114M
| – | – |
-3,350,000
| Closed | -$27.7M |
|
15
Kratos Defense & Security Solutions
KTOS
$8.63B
| – | – |
-200,014
| Closed | -$5.49M |
|
16
NexGen Energy
NXE
$5.82B
| – | – |
-1,000,000
| Closed | -$2.76M |
|
17
Ocular Therapeutix
OCUL
$1.96B
| – | – |
-53,934
| Closed | -$1.12M |
|
18
QuantumScape Corp
QS
$3.6B
| – | – |
-1,000
| Closed | -$84K |
|
|
RETA
19
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-525,000
| Closed | -$64.9M |
|
|
ONCR
20
DELISTED
Oncorus, Inc.
ONCR
| – | – |
-78,043
| Closed | -$2.52M |
|
|
APTO
21
DELISTED
Aptose Biosciences, Inc.
APTO
| – | – |
-6,444
| Closed | -$12.7M |
|
|
CNCE
22
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| – | – |
-680,000
| Closed | -$8.6M |
|
|
MNDT
23
DELISTED
Mandiant, Inc. Common Stock
MNDT
| – | – |
-690,000
| Closed | -$15.9M |
|
Similar funds
SCM
FWM
TOPU
TGI
GIP
LCMP
SCM
TA
Corriente Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Corriente Advisors held 23 positions worth $272M, down 35% from $420M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Corriente Advisors withdrew a net $117M in Q1 2021, closing 13 positions and reducing 1 holding. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $64.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 53% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Corriente Advisors opened a new position in Teledyne Technologies worth $22.8M.
- Corriente Advisors's largest Q1 2021 buy was Teledyne Technologies: 55,000 shares worth $22.8M.
- Corriente Advisors added most to Cardiff Oncology in Q1 2021, an estimated $9.54M increase.
- Corriente Advisors's biggest Q1 2021 reduction was Replimune Group, cutting an estimated $5.99M.
- Corriente Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021, selling an estimated $64.9M.
- Corriente Advisors's ten largest holdings make up 100% of its $272M portfolio in Q1 2021.
- Corriente Advisors opened 4 new positions and closed 13 in Q1 2021.
- Corriente Advisors's portfolio value fell 35% quarter-over-quarter to $272M.
Based on Corriente Advisors's 13F filing for Q1 2021, filed 18 May 2021.